By PPN Staff
The FDA approved nintedanib (Ofev, Boehringer Ingelheim Pharmaceuticals Inc.) capsules to slow the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic sclerosis or scleroderma (SSc-ILD).
Nintedanib is the first FDA-approved treatment for this rare lung condition, the agency announced.